Biotechnology company developing precision covalent medicines using a proprietary chemoproteomics discovery platform
Biotechnology company developing precision covalent medicines using a proprietary chemoproteomics discovery platform. The platform maps histidine-, tyrosine-, and lysine-based binding sites on disease-causing proteins to enable rational small-molecule drug discovery, including for targets that are difficult to address with conventional approaches. Its therapeutic development focus includes oncology.